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Abstract Atherosclerosis is an immunoinflammatory pro-
cess that involves complex interactions between the vessel
wall and blood components and is thought to be initiated by
endothelial dysfunction [Ross (Nature 362:801–809, 1993);
Fuster et al. (N Engl J Med 326:242–250, 1992); Davies
and Woolf (Br Heart J 69:S3–S11, 1993)]. Extracellular
nucleotides that are released from a variety of arterial and
blood cells [Di Virgilio and Solini (Br J Pharmacol 135:831–
842, 2002)] can bind to P2 receptors and modulate pro-
liferation and migration of smooth muscle cells (SMC),
which are known to be involved in intimal hyperplasia that
accompanies atherosclerosis and postangioplasty restenosis
[Lafont et al. (Circ Res 76:996–1002, 1995)]. In addition,
P2 receptors mediate many other functions including plate-
let aggregation, leukocyte adherence, and arterial vaso-
motricity. A direct pathological role of P2 receptors is
reinforced by recent evidence showing that upregulation and
activation of P2Y2 receptors in rabbit arteries mediates
intimal hyperplasia [Seye et al. (Circulation 106:2720–
2726, 2002)]. In addition, upregulation of functional P2Y
receptors also has been demonstrated in the basilar artery of
the rat double-hemorrhage model [Carpenter et al. (Stroke
32:516–522, 2001)] and in coronary artery of diabetic
dyslipidemic pigs [Hill et al. (J Vasc Res 38:432–443,
2001)]. It has been proposed that upregulation of P2Y
receptors may be a potential diagnostic indicator for the
early stages of atherosclerosis [Elmaleh et al. (Proc Natl
Acad Sci U S A 95:691–695, 1998)]. Therefore, particular
effort must be made to understand the consequences of
nucleotide release from cells in the cardiovascular system
and the subsequent effects of P2 nucleotide receptor
activation in blood vessels, which may reveal novel
therapeutic strategies for atherosclerosis and restenosis after
angioplasty.
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Introduction
Atherosclerosis is a pathological phenomenon primarily
affecting the large conduit arteries, for example the aorta,
coronary, carotid iliac, and femoral arteries. The develop-
ment of atherosclerotic lesions in arteries involves the
intimal recruitment of smooth muscle cells (SMC) within
the blood vessel wall, and also the infiltration of blood-
derived cells [1]. This process necessitates the proliferation
and migration of SMC from the underlying media and the
endothelial adhesion of leukocytes and their infiltration into
the subendothelium. A similar intimal accumulation of
SMC also takes place during the postangioplasty restenotic
process. Although the factors involved in intimal cell
recruitment are not clearly identified, it is becoming evident
that endothelial dysfunction is a key factor in the
development of vascular disease. Experimental evidence
suggests that an intact endothelium plays a central role in
maintaining a low proliferative state of SMC under normal
conditions [10]. In arterial injury, endothelial cells, SMC,
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mitogens, including ATP and other nucleotides (see [4] for
review). Activation of P2 nucleotide receptors has been
shown to induce not only the proliferation and migration of
vascular SMC but also apoptosis, a process involved in the
evolution of the atherosclerotic plaque [11]. In addition, P2
receptors mediate both vasorelaxation and vasoconstriction
of arteries that may be involved in the vascular remodeling
accompanying atherosclerosis and postangioplasty resteno-
sis [5]. A better understanding of the causative agents and
mechanisms of proliferation and migration of vascular
SMC as well as recruitment of blood-derived cells by the
endothelium could lead to prevention, attenuation, or even
reversal of intimal thickening, which may dramatically
reduce morbidity and mortality from vascular diseases such
as atherosclerosis and restenosis after angioplasty. In this
respect, a better understanding of the physiological role of
P2 receptors in both normal and pathological blood vessels
could potentially lead to a breakthrough in the fight against
vascular disease.
P2 receptors in the cardiovascular system
Extracellular nucleotides bind to cell surface receptors
known as P2 receptors, which are present in many tissues.
To date, these receptors have been classified into two main
families: the P2X receptors that are ligand-gated ion
channels comprised of homo- or hetero-oligomers [12] and
P2Y receptors that are seven membrane spanning receptors
coupled via G proteins (Gq/11 or Gi/o) to phospholipase C
(PLC) and/or adenylate cyclase [12–14]. In turn, PLC
activation generates inositol 1,4,5-triphosphate (IP3), a
mediator of Ca
2+ release from intracellular stores, and
diacylglycerol, an activator of protein kinase C (PKC),
whereas adenylate cyclase generates cyclic adenosine
monophosphate (cAMP), an activator of protein kinase A
(PKA). The cloning of seven P2X (P2X1, P2X2, P2X3,
P2X4, P2X5, P2X6, P2X7) and eight P2Y (P2Y1, P2Y2,
P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, P2Y14) receptor sub-
types has made it possible to use molecular and pharmacol-
ogical approaches to study the distribution and functional
properties of specific P2 receptor subtypes at the tissue and
cellular level.
P2 receptors in vascular cells
The normal arterial wall consists of three layers: the intima,
media, and adventitia. The single layer of endothelial cells
facing the vessel lumen is a very important component of
the vascular wall in terms of releasing both vasodilators
such as nitric oxide (NO) and prostacyclin (PGI2) and
vasoconstrictors like thromboxane A2 and endothelin. The
principal P2Y receptor subtypes that have been functionally
characterized in endothelial cells are P2Y1 and P2Y2, but
mRNAs for P2Y4 and P2Y6 receptors have also been
detected [4]. Endothelium-dependent vasorelaxation has
been attributed to the release of NO and PGI2 after binding
of nucleotides to P2Y1 and P2Y2 receptors in endothelial
cells [15], whereas vasoconstrictor effects in SMC result
from the action of nucleotides on P2Y2 and P2X receptors
[16, 17]. In most blood vessels, P2Y1 receptors for ADP are
present on the endothelium and regulate vasodilatation by
Ca
2+-dependent (PLC-mediated) activation of nitric oxide
synthase (NOS) and generation of endothelial-dependent
relaxing factor (EDRF) (see [4] for review). Endothelial
prostacyclin production is also stimulated by P2Y1 and
P2Y2 receptors, but this seems to play a minimal role in
vasodilatation, at least under physiological conditions (see
[18] for review). Recent studies have indicated that in the
aorta of P2Y2-null mice the endothelium-dependent relax-
ation by ATP and ATPgS was inhibited, demonstrating the
role of the P2Y2 receptors, but that a relaxation by UTP and
UDP was maintained, suggesting the additional involve-
ment of P2Y6 receptors [19]. The majority of the cells in
intact blood vessels are SMC, which occupy most of the
media, and are involved in vasoconstriction and vaso-
relaxation of the vessel. P2Y2Rs in SMC mediate the
induction of immediate-early and delayed-early cell cycle-
dependent genes, consistent with a role for P2Y2Rs in
vascular proliferation of SMC [20, 21]. A recent study
demonstrated that P2Y2 is the predominant functional
receptor that responds to ATP and UTP in rat aortic SMC
[22]. In human cerebral arteries, P2Y6 seems to be the
predominant subtype and induces vasoconstriction when
activated by UDP/UTP [23, 24]. This is consistent with
findings from rat pulmonary and mesenteric arteries [25,
26]. In addition, a recent study on P2X1 knockout mice
further supports the prominent contractile effect of the
P2Y6 subtype in mesenteric arterial trees [27]. Taken
together, it seems that the principal receptor mediating
UTP/UDP-induced contractile responses in blood vessels
might be the P2Y6 subtype. Other studies have reported the
presence of both P2Y4 and P2Y6 receptors in rat aortic
SMC [21, 28, 29]. P2Y1 receptors are expressed in SMC of
a number of blood vessel types and like their EC counter-
parts mediate vasodilatation most likely through the
activation of K
+ channels (see [18] for review). The
presence of several P2X receptor subtypes also has been
reported in human saphenous vein SMC, including P2X1,
P2X2, P2X4, and P2X7 receptors [30]. The outermost layer
of the blood vessel consists of connective tissue and
fibroblasts, which have not been appreciated in the
regulation of vascular tone. A recent study showed that
fibroblasts can migrate into the neointima, suggesting their
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diseases such as atherosclerosis and restenosis after
angioplasty [31]. Since human and rat fibroblasts are
known to express P2Y1, P2Y2,P 2 Y 4, P2Y6, P2X3, P2X4,
and P2X7 receptors [32], further investigation is needed to
establish the role of fibroblast P2 receptors in either
physiological or pathophysiological conditions.
P2 receptors in blood cells
G protein-coupled P2Y receptors whose activation leads to
intracellular calcium mobilization have been observed in
neutrophils [4, 33, 34], and turkey erythrocytes express both
P2Y1 and P2X7 receptors [35, 36]. ATP and UTP act as
secretagogues by binding to P2Y2Rs to enhance exocytosis
of primary granules in neutrophils [37]. In macrophages,
ATP activates a P2X7 receptor that differs from other ligand-
gated ion channel P2X receptors by its ability to generate
plasma membrane pores when activated [38]. Human T
lymphocytes also have been shown to express P2X7
receptors [39]. Human monocytes and macrophages coex-
press P2X1, P2X4, and P2X7 receptors, whereas granulocytes
only express P2X7 receptors [40]. P2Y1,P 2 Y 2, and P2Y6
receptors also are expressed in monocytes, B lymphocytes,
and polymorphonuclear granulocytes [41]. Human platelets
express P2Y1,P 2 Y 12, and P2X1 receptors [42–44]. Thus, the
diversity of P2 receptor expression in blood cells, as well as
endothelial cells, SMC, and fibroblasts, suggests that this
receptor superfamily plays a significant role in the regulation
of cardiovascular functions.
P2 receptors regulate nucleotide-induced vascular
smooth muscle cell proliferation
Proliferation of SMC is a hallmark of vascular diseases
such as atherosclerosis and restenosis following angioplas-
ty. ATP and other nucleotides are released by aggregating
platelets and damaged vascular cells, such as endothelial
cells and SMC in pathological or stress conditions [45].
Extracellular nucleotides can act via P2X and P2Y
receptors to induce acute responses such as the regulation
of vascular tone [46]. However, it is generally believed that
the ionotropic P2X receptors do not mediate the chronic
responses of nucleotides such as cell proliferation. The
mitogenic effect of extracellular nucleotides on vascular
SMC (VSMC) has been known for years [47]. However, a
potent antiproliferative effect of UTP on VSMC also has
been reported in human arterial and venous SMC [48]. In
either case, the P2 receptor subtype(s) responsible for these
effects on the proliferation of VSMC has not been
determined. Earlier studies have shown that ATP or UTP
increased DNA and protein synthesis in subcultured rat
aortic VSMC [49, 50]. In the same cell culture model,
however, Malam-Souley et al. [51] were unable to detect
increases in DNA synthesis after ATP/UTP stimulation,
although ATP or UTP upregulated the expression of mRNA
to several cell cycle progression-related genes. Because
P2X receptor agonists were essentially inactive, it was
concluded that a P2U-like receptor (now termed P2Y2) was
responsible for the mitogenic effects of ATP/UTP. Howev-
er, the role of a P2Y4 receptor cannot be excluded, because
the nucleotide agonist profile between rat P2Y2 and P2Y4
receptors is essentially indistinguishable [52]. Indeed,
Harper et al. [53] suggested that the P2Y4 receptor
mediated ATP/UTP-induced proliferation of rat aortic
VSMC. Recent studies indicated that ATP, UTP, or ITP,
three agonists of the cloned porcine P2Y2 receptor,
increased DNA and protein synthesis and cell number in
coronary artery SMC [54]. Indeed, treatment of pig cor-
onary artery SMC with UTP, ATP, or ITP caused a
concentration-dependent increase in DNA and protein
synthesis and cell number, whereas UDP only caused a
small increase in protein synthesis. Intriguingly, ATP was
much more potent and efficacious than UTP, ITP, and UDP
in increasing DNA synthesis and expression of PCNA, a
protein marker of cell proliferation, suggesting that anoth-
er receptor may contribute to the proliferative response
[54]. In vivo experiments have shown that intimal thicken-
ing of collared rabbit carotid arteries was greatly enhanced
by in situ UTP application and was closely associated with
osteopontin expression in medial SMC [6]. Osteopontin is
chemotactic for SMC and is associated with arterial smooth
muscle cell proliferation [55]. Moreover, both UTP and
ATP increased osteopontin expression in cultured SMC,
whereas ADP, UDP, and 2-MeSATP were ineffective,
which suggests a role for the P2Y2R in which ATP and
UTP are equipotent. Direct evidence for involvement of the
P2Y2R was provided by inhibition of UTP-induced
osteopontin expression in cultured SMC by P2Y2 antisense
oligonucleotides [6]. P2Y6 receptors also have been shown
to mediate proliferation of SMC in rat aorta [56].
Role of P2 receptors in the migration of vascular SMC
Recent studies indicate that the extracellular nucleotides
ATP, ADP, UTP, and UDP serve as directional cues for the
migration of rat aortic SMC [57]. At identical concen-
trations, the most powerful migratory response induced by
these nucleotides was elicited by UTP. Nucleotide-induced
migration of SMC is the consequence of both chemotaxis
and chemokinesis and may result either from the activation
of one particular P2 nucleotide receptor subtype or from
activation of several P2 receptor subtypes. The ability of
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SMC supports the hypothesis that this response could have
physiological consequences and is essentially mediated by
P2Y2 receptor activation without excluding participation of
other P2Y receptor subtypes. The difference in the capacity
of UTP and ATP to elicit migration of SMC could be due to
the inhibition of nucleotide-induced cell migration by
adenosine generated from ATP catabolism by cell surface
ectonucleotidases. Indeed, ATP and UTP were equally
effective in causing migration of SMC when ATP was
prevented from degradation by addition of the ectonucleo-
tidase inhibitor a,β-methylene-ATP [57]. Several P2Y
receptor subtypes could be involved in nucleotide-induced
migration of SMC. It has been shown in rat aortic SMC that
the P2Y2 receptor is the predominant P2Y receptor subtype
[28, 58], whereas lower levels of P2Y4 and P2Y1 receptor
mRNA were detected [58]. The very low level of P2Y1
receptor mRNA expression was consistent with the absence
of ADP-induced migration of cultured rat aortic SMC,
demonstrating that P2Y1 is not involved in this process
[58]. In addition, the same study showed that a commer-
cially available solution of hexokinase-treated UDP (UTP-
free) induced cell migration equally well as untreated UDP,
thereby demonstrating that UDP is chemotactic for aortic
SMC by activation of the P2Y6 receptor. Conversely,
migration of rat aortic SMC induced by UTP occurred
even when UTP degradation by nucleoside diphosphate
kinase was inhibited, demonstrating the involvement of
P2Y2 and/or P2Y4 receptor(s) [58].
The increased migration of SMC in response to extracel-
lular nucleotides could be related to increases in extracellular
matrix (ECM) protein expression. Indeed, previous studies
have shown that UTP induces osteopontin expression in rat
and rabbit aortic SMC [51, 6]. Increased expression of
osteopontin, an RGD-containing ECM protein, is associated
with the activation of rat arterial SMC in vitro and in vivo
[57]. The increase in osteopontin expression plays a key role
in UTP-induced migration of rat aortic SMC, since a
monoclonal antibody against osteopontin fully abolished
UTP-induced migration [57], whereas an antibody against
vitronectin, another ECM protein also involved in migration
of human SMC [59], had no effect on the migration of rat
aortic SMC [57]. UTP induces increases in osteopontin
mRNA expression by increasing both osteopontin mRNA
stabilization and osteopontin promoter activity [60]. Recent
studies have shown that activation of an AP-1 binding site
located 76 bp upstream of the transcription start in the rat
osteopontin promoter is involved in UTP-induced osteopon-
tin expression. Using a luciferase promoter deletion assay,
Renault et al. [61] identified a new region of the rat
osteopontin promoter (-1837 to -1757) that is responsive to
UTP. This region contains an NFκB site located at -1800 and
an Ebox located at -1768. Supershift electrophoretic mobility
shift and chromatin immunoprecipitation assays identified
NFκB and USF-1/USF-2 as DNA binding proteins induced
by UTP. Using dominant negative mutants of IκB kinase and
USF transcription factors, it was confirmed that NFκBa n d
USF-1/USF-2 are involved in the UTP-induced expression
of osteopontin.
This ability of nucleotides to act as chemoattractants for
rat arterial SMC in a concentration range potentially found
in pathological vessels [62] and the findings of previous
studies demonstrating the mitogenic activity of extracellular
nucleotides for these cells suggest that nucleotides released
from mechanically stretched vascular or damaged cells
during the angioplasty process may participate in arterial
wall remodeling.
Role of P2 receptors in nucleotide-induced vascular
inflammation
In addition to their mitogenic effects, extracellular nucleo-
tides may also cause cell recruitment by inducing lympho-
cyte and macrophage adhesion to human pulmonary artery
endothelial cells as demonstrated in vitro [63]. Nucleotides
can also modulate rat aortic smooth muscle cell adhesion
and migration by increasing the expression of osteopontin
[51, 57], a protein involved in both processes. Moreover,
extracellular nucleotides may play a role in intra-arterial
attraction of monocytes by inducing an increased expres-
sion of monocyte-chemoattractant protein-1 by arterial
SMC [21]. Stimulation of P2 receptors is coupled to the
release of the proinflammatory cytokines interleukin (IL)-
1β, IL-1a, IL-8, and tumor necrosis factor (TNF)-a (see [4]
for review) that are of obvious relevance to inflammation in
atherosclerosis. Activation of P2X7 receptors on mono-
cytes/macrophages enhances release of proinflammatory
cytokines that modulate NO production and expression of
inducible nitric oxide synthase (iNOS) (see [64]f o r
review), mediators of immune cell activation that is an
early step in atherosclerotic lesion development.
Monocyte recruitment into the vessel wall is a complex
process that includes cell rolling, firm attachment, and
directed migration. It is now becoming evident that
adhesion molecules such as VCAM-1 play an important
role in leukocyte adherence to vascular endothelial cells
[65, 66]. VCAM-1 expression is induced or upregulated by
proinflammatory cytokines such as TNF-a and IL-1β in
cellular components of the arterial wall including endothe-
lial cells, smooth muscle cells, and fibroblasts [67-69]. ATP
and UTP have been shown to induce cell-cell adhesion in a
human monocyte/macrophage lineage and neutrophil ad-
herence to human endothelial cell monolayers [63, 70].
Recent studies have shown that local UTP delivery via
an osmotic pump to collared rabbit carotid arteries induced
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low-density lipoprotein (LDL), a response that was medi-
ated by activation of P2Y2 receptors [6]. Leukocyte
migration depends on the activities of adhesion proteins
(e.g., selectins and integrins) on leukocytes and vascular
endothelial cells. We have demonstrated that activation of
P2Y2 receptors in endothelial cells causes the expression of
VCAM-1 that mediates the adherence of monocytes to
vascular endothelium [71], leading to their penetration into
the vessel wall to promote arterial inflammation associated
with atherosclerosis.
Recent studies have revealed that a Src homology-3 (SH3)
binding domain in the C-terminal tail of the P2Y2 receptor
promotes the nucleotide-induced association of Src with the
P2Y2 receptor, leading to the transactivation of growth factor
receptors, such as the epithelial growth factor (EGF) and
vascular endothelial growth factor (VEGF) receptors, and
nucleotide-induced upregulation of VCAM-1 [72, 73]. Since
leukocyte infiltration and migration are key processes
involved in atherosclerosis, these findings suggest that
P2Y2 receptors represent a novel target for reducing arterial
inflammation associated with cardiovascular disease.
P2 receptors in vascular apoptosis
Apoptosis (programmed cell death) has been reported to
occur in various vascular diseases such as atherosclerosis,
restenosis, and hypertension [74, 75]. The major cell types
undergoing apoptosis in human atherosclerotic lesions are
arterial SMC [11, 76–78] and macrophages [79]. In
restenosis following balloon angioplasty, there is a peak in
the proliferation and apoptosis of rat vascular SMC 14 days
postangioplasty [76]. Furthermore, apoptosis of arterial
SMC has been described in animal models of intimal
thickenings [80] and probably takes part in the normal
process involved in the control of hyperplasia. In contrast,
apoptosis of SMC in advanced human atherosclerotic
plaques may destabilize the fibrous lesion to promote
plaque rupture and its clinical consequences.
As a mediator of cell-to-cell communication, ATP can
trigger a variety of biological responses after being rapidly
released in large amounts from various sources, including
activated platelets, endothelial cells, nerve terminals, antigen-
stimulated T cells, and other cell types following hypoxia,
stress, and tissue damage. For example, in human umbilical
cord vein endothelial cells (HUVEC), a substantial release of
ATP (and UTP) is induced by shear stress [81], which may
lead to alterations in the balance between proliferation and
apoptosis regulated by P1 adenosine and P2 (particularly
P2X7)n u c l e o t i d er e c e p t o r s[ 82]. P2X7 and P1 receptors have
been previously linked to apoptosis in other cell types,
including immune cells, astrocytes, and thymocytes [83–85].
The P2X7R also has been shown to mediate ATP-induced
cell death in human embryonic kidney cells [86], human
cervical epithelial cells [87], and primary rat cortical neurons
[88]. In human arterial SMC, adenosine-induced apoptosis is
essentially mediated via the A2b-adenosine receptor subtype
and involves a cAMP-dependent pathway [89].
As an important constituent of atherosclerotic plaques,
fibroblasts share several features with smooth muscle cells.
In human fibroblasts, P2X7 was identified as the main
nucleotide receptor involved in the high glucose concen-
tration-dependent responses modulated by ATP, including
morphological changes, enhanced apoptosis, caspase-3
activation, and IL-6 release [90]. In the immune system,
ATP also plays important roles through nucleotide receptors
in leukocyte functions. P2X7 receptor-mediated apoptosis
has been demonstrated in various types of leukocytes,
including a lymphocytic cell line, murine thymocytes,
murine peritoneal macrophages, human macrophages,
mesangial cells, dendritic cells, and microglial cells [83,
91–96]. Extracellular ATP acting via the P2X7 receptor
activates the transcription factor NFκB by selectively
targeting NFκB p65 (Rel A) in the N9 mouse microglial
cell line [97]. It also has been reported that the P2X7
receptor modulates macrophage production of TNF-a, IL-
1β, and nitric oxide (NO) following lipopolysaccharide
(LPS) exposure [98], consistent with a role for the P2X7
receptor in inflammation. In HUVEC, TNF-a markedly
increases apoptotic cell death via the activation of caspase-3
[74]. Recent reports indicate that ATP/ADP activate NFκB
and induce apoptosis probably through P2X7 receptors in
porcine aortic endothelial cells [99]. These studies have
provided compelling evidence suggesting a role for P2 and
P1 receptor-mediated apoptosis in vascular diseases; how-
ever, further studies are needed to determine the precise
pathways involved and to accumulate direct evidence that
these pathways contribute significantly to the development
of atherosclerosis, hypertension, and restenosis.
Modulation of P2 receptors in vascular injury
Experimental arterial intimal hyperplasia can be induced by
balloon angioplasty or by the perivascular placement of a
silicone collar around an artery. An influx of leukocytes
precedes the migration and proliferation of vascular SMC
into the intima in both these models [100]. In normal adult
rat aorta, P2Y2 mRNA was found in the endothelial cell
lining, while a sustained expression of P2Y2 mRNA was
detected in few medial SMC [20]. In contrast, P2Y2 mRNA
was detected in all medial SMC of rat fetal aortas and in
most of the aortic SMC of intimal lesions after balloon
angioplasty, with an overexpression in cells lining the
lumen both 1 and 3 weeks after injury.
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triphasic [100]. The first phase is characterized by vascular
infiltration of leukocytes beginning 2 h after collar
placement around a rabbit carotid artery. The second phase
begins within 12 h of collar placement and is characterized
by medial replication of SMC. The third phase is
characterized by the appearance, beginning at day 3 after
collar placement, of subendothelial SMC. In situ hybrid-
ization with sham-operated rabbit carotid arteries indicated
that P2Y2 mRNA expression was localized to CD31-
positive aortic endothelial cells and not medial SMC [6].
High levels of P2Y2 mRNA were detected in medial SMC
3 days after collar placement, before appearance of neo-
intima. At day 14, all intimal and medial SMC were P2Y2
positive. Fura-2 digital imaging of single SMC, used to
measure changes in myoplasmic calcium concentration in
response to P2Y receptor agonists, confirmed an increase in
P2Y2 receptor activity. However, the same study showed
that P2Y4 mRNA was equivalently expressed in sham-
operated and collared arteries or cultured rabbit carotid
SMC, whereas P2Y6 mRNA was not detected in carotid
arteries or cultured SMC. In a more recent study, it was
shown that P2Y2 receptor upregulation occurs in stented
porcine coronary artery, a clinically relevant model of
arterial injury [54]. P2Y2 receptor mRNA levels were
significantly increased in coronary SMC dispersed from
stented segments of coronary arteries 3 weeks after stent
angioplasty compared with SMC from unstented segments.
There was no significant difference observed in levels of
P2Y6 mRNA in the stented and unstented artery segments,
whereas P2Y4 receptor mRNA was undetectable.
Upregulation of functional P2Y receptors also occurs in
the basilar artery of the rat double-hemorrhage model [7],
in the coronary artery of diabetic dyslipidemic pigs [8], and
in human atherosclerotic lesions (Seye and Desgranges,
unpublished data). It has been proposed that upregulation of
P2Y receptors could be a potential diagnostic indicator for
the early stages of atherosclerosis [9]. Interestingly, a more
recent study showed that high shear stress, associated with
vascular diseases, can selectively upregulate P2Y2 and
P2Y6 receptors in perfused arterial SMC [101]. P2X1 and
P2X4 receptors have been shown to be upregulated in rabbit
intimal thickenings [102]. Taken together, these findings
strongly suggest that at least some P2 receptor subtypes
(most notably P2Y2) are implicated in the development of
vascular disease.
Pathophysiological significance of P2 receptor
modulation in vascular injury
Migrating and proliferating SMC in the arterial media,
together with infiltrating macrophages and T lymphocytes,
are the main cell types that comprise atherosclerotic and
restenotic lesions [1]. In the early stages of intimal
hyperplasia, SMC are modified from a differentiated,
contractile phenotype to an immature, synthetic phenotype,
and this enables them to migrate into the intima, to
proliferate, and to secrete extracellular matrix components.
In many respects, this shift in phenotype is a reversal of the
normal differentiation pattern of vascular SMC during fetal
and early postnatal life [103, 104]. However, there is still a
lack of knowledge concerning the phenotypic regulation of
SMC during vasculogenesis and vascular disease. A high
level of P2 receptor expression could be related to the altered
phenotype of SMC in intimal thickenings. Partially dediffer-
entiated SMC are found in rat arterial intimal lesions after
balloon angioplasty [105, 106], and their phenotype has been
compared with that of newborn rat aortic SMC [107].
Interestingly, it has been reported that medial SMC of rat
embryonic aorta also exhibit high P2Y2 expression, similar
to intimal thickenings [20]. Other studies have shown that
P2Y1 and P2Y2 receptor transcripts are strongly upregulated
with phenotypic changes in rat SMC, whereas P2X1 mRNA
is completely downregulated, and P2Y4 and P2Y6 mRNA
levels are unchanged [58, 28]. Taken together, these and
other results suggest that P2Y2 receptor expression is
upregulated in the entire cell population of intimal thicken-
ings and is closely associated with a poorly differentiated
phenotype of SMC. The dramatic increase in P2Y2 mRNA
expression observed in balloon angioplasty-induced intimal
lesions would suggest increased activity of extracellular
nucleotides with consequent enhancement of cell prolifera-
tion and vasoreactivity. Indeed, extracellular nucleotides,
particularly ATP and UTP, have been shown to induce cell
cycle progression and proliferation of cultured arterial SMC
[21, 49, 50, 51] and vasoconstriction in the absence of
endothelial cells [17, 108, 109]. Since both neointimal
hyperplasia and vasoconstrictive remodeling have been
found to be involved in postangioplasty restenosis [1, 5,
107, 110], these findings suggest that extracellular nucleo-
tides may play a significant role in this process, at least as
long as functional endothelial cells, which regulate intimal
thickening [111, 112] and nucleotide-induced vasorelaxation
[113, 114], are not regenerated.
Increased P2Y2 receptor expression in the neointima
may by itself be sufficient to enhance the local effects of
extracellular nucleotides on the proliferation of SMC.
Although the expression of other P2 receptors has been
described in arterial SMC [21, 29, 115], the P2Y2 receptor
seems to be more specifically involved in the response of
SMC to ATP and UTP [116], particularly in the potentiation
of proliferation [21, 50]. The effects of extracellular
nucleotides are not only dependent on the nature and
number of P2 receptors present on target cells, but also on
the local concentrations of nucleotide agonists. Although
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difficult to measure, various in vitro experiments suggest
that extracellular nucleotides are released from blood and
vascular cells exposed to various physicochemical con-
ditions, e.g., stress, hypoxia, and other factors [117, 118,
119] associated with the angioplasty process.
P2Y2 receptorsinSMCareinvolvedinnucleotide-induced
constriction of normal arteries [17, 108, 109]. Long lasting
alterations in vasomotricity after endothelial cell denudation,
resulting in increased sensitivity to vasoconstrictive sub-
stances, have previously been demonstrated [113, 114]. It
appears that like other receptors for vasoconstrictive factors
such as angiotensin II [120], endothelin [121], and platelet-
derived growth factor (PDGF) [122], which are overex-
pressed in neointima, P2Y2 receptors may play an important
role in controlling the vasoactive properties of pathological
arteries, particularly in chronic constriction at the lesion site
that is postulated to be one of the processes leading to
postangioplasty restenosis [5, 110].
Conclusion
P2 receptor subtypes, including P2Y2, P2X1, and P2X4,
appear to play a role in responses to endothelial injury that
are thought to be key events in the initiation of atheroscle-
rosis and restenosis after angioplasty. P2Y2R upregulation
and activation in endothelial cells and SMC promote
leukocyte transmigration and intimal thickening in arteries
of animal models of vascular injury, suggesting a possible
regulatory role for this receptor in the mechanisms leading
to neointimal hyperplasia after angioplasty. Although there
are no selective P2Y2 receptor antagonists yet available,
recent progress in siRNA technology has made it possible
to design small RNA interference molecules that can
selectively inhibit P2 receptor subtype expression. Such
molecules can be efficiently delivered into the vessel wall
using adenoviral vectors. In addition, P2 receptor transgenic
mice (i.e., mice in which the relevant receptor subtype has
been deleted or overexpressed) will be valuable tools to
substantiate the role that nucleotides and P2 receptors play
in the etiology of cardiovascular disease. Further delinea-
tion of the signaling pathways involved in these P2
receptor-mediated processes may help limit or prevent
vascular diseases such as atherosclerosis and restenosis
after angioplasty.
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